Moderna's vaccine reduces melanoma recurrence risk
A study presented at the American Society of Clinical Oncology conference showed that an experimental vaccine developed by Moderna, based on messenger RNA technology, combined with the immunotherapy "Ketruda," significantly reduces the risk of skin cancer recurrence after five years compared to treatment with either one alone. The study found that the rate of cancer recurrence dropped to 31.2% among those who received the combined therapy, compared to 50.9% for those who received "Ketruda" only, with the survival rate increasing to 92.2%. The results confirm that combining the vaccine with immunotherapy can improve patient outcomes in the treatment of skin cancer.
Size: 120%Text Size
Notice: This Is an AI-Generated Summary
Comments (0)